


RESEARCH ARTICLE

Bioassays guided isolation of berberine from *Berberis lycium* and its neuroprotective role in aluminium chloride induced rat model of Alzheimer's disease combined with insilico molecular docking

Hammad Ismail^{1*}, Dania Khalid¹, Durdana Waseem², Muhammad Umar Ijaz³, Erum Dilshad⁴, Ihsan-ul Haq⁵, Muhammad Zeeshan Bhatti⁶, Sadaf Anwaar⁷, Madiha Ahmed², Samreen Saleem⁸

1 Department of Biochemistry and Biotechnology, University of Gujrat, Gujrat, Pakistan, **2** Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan, **3** Department of Zoology, Wildlife and Fisheries, University of Agriculture, Faisalabad, Pakistan, **4** Department of Bioinformatics and Biosciences, Faculty of Health and Life Sciences, Capital University of Science and Technology, Islamabad, Pakistan, **5** Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan, **6** Department of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan, **7** Department of Biological Sciences, International Islamic University, Islamabad, Pakistan, **8** Department of Nutrition and Lifestyle Medicine, Health Services Academy, Islamabad, Pakistan

* hammad.ismail@uog.edu.pk



OPEN ACCESS

Citation: Ismail H, Khalid D, Waseem D, Ijaz MU, Dilshad E, Haq I-u, et al. (2023) Bioassays guided isolation of berberine from *Berberis lycium* and its neuroprotective role in aluminium chloride induced rat model of Alzheimer's disease combined with insilico molecular docking. PLoS ONE 18(11): e0286349. <https://doi.org/10.1371/journal.pone.0286349>

Editor: Milkyas Endale, Adama Science and Technology University, ETHIOPIA

Received: December 25, 2022

Accepted: May 13, 2023

Published: November 1, 2023

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0286349>

Copyright: © 2023 Ismail et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective

Berberis lycium is an indigenous plant of Pakistan that is known for its medicinal properties. In the current study, we investigated the anti-Alzheimer's effect of berberine isolated from *Berberis lycium*.

Methods

Root extract of *B. lycium* was subjected to acetylcholinesterase inhibition assay and column chromatography for bioassays guided isolation of a compound. The neuroprotective and memory improving effects of isolated compound were evaluated by aluminium chloride induced Alzheimer's disease rat model, elevated plus maze (EPM) and Morris water maze (MWM) tests. Levels of dopamine and serotonin in rats brains were determined using HPLC. Moreover, western blot and docking were performed to determine interaction between berberine and β -secretase.

Results

During fractionation, ethyl acetate and methanol (3:7) fraction was collected from solvent mixture of ethyl acetate and methanol. This fraction showed the highest anti-acetylcholinesterase activity and was alkaloid positive. The results of TLC and HPLC analysis indicated the presence of the isolated compound as berberine. Additionally, the confirmation of

Data Availability Statement: All relevant data are within the paper and its [Supporting Information](#) files.

Funding: This research was supported by the Committee on Scientific and Technological Cooperation of the Organization of Islamic Conference, Islamabad, Pakistan and the International Foundation for Science, Stockholm, Sweden, under grant no. I-1-F-6453-1 to Dr. Hammad Ismail, Assistant Professor University of Gujrat (<https://www.ifs.se/>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

isolated compound as berberine was carried out using FTIR and NMR analysis. *In vivo* EPM and MWM tests showed improved memory patterns after berberine treatment in Alzheimer's disease model. The levels of dopamine, serotonin and activity of antioxidant enzymes were significantly ($p < 0.05$) enhanced in brain tissue homogenates of berberine treated group. This was supported by decreased expression of β -secretase in berberine treated rat brain homogenates and good binding affinity of berberine with β -secretase in docking studies. Binding energies for interaction of β -secretase with berberine and drug Rivastigmine is -7.0 kcal/mol and -5.8 kcal/mol respectively representing the strong interactions. The results of docked complex of secretase with berberine and Rivastigmine was carried out using Gro-macs which showed significant stability of complex in terms of RMSD and radius of gyration. Overall, the study presents berberine as a potential drug against Alzheimer's disease by providing evidence of its effects in improving memory, neurotransmitter levels and reducing β -secretase expression in the Alzheimer's disease model.

Introduction

Alzheimer's disease (AD) is a common neurodegenerative disorder characterized by progressive memory loss. It is estimated that about 4.5 million people in America have AD. As the elderly population continues to grow, the incidences of AD may increase to 13.2 million by 2050 [1]. It is more alarming in developing countries where approximately 70% of the world's population aged 60 and above lives. According to the data of World Health Organization (WHO) published in 2017, deaths due to AD in Pakistan were 15,428 (1.3%) of the total deaths, and the age-adjusted death rate was 15.35 per 100,000 population [2]. Impact of AD on health care costs including direct cost, indirect cost, and social services, is currently estimated to be greater than \$100 billion per year [3].

Although the cause of AD is not fully understood; however, observations reveal the presence of amyloid beta ($A\beta$) protein, tau protein plaques, and neurofibrillary components. Initially, hippocampus region of the brain involved in memory and learning is affected, which then tangle the entire brain [4]. There are decreased levels of acetylcholine, dopamine and serotonin that contribute to amyloid plaque toxicity and memory impairment in AD patients [5, 6].

According to WHO, almost three billion people that make approximately 80% of developing countries' population, rely on complementary and alternative medicines [7, 8]. This huge interest in complementary and alternative medicines is due to various limitations of synthetic drugs, such as side effects, high cost, and multidrug resistance [9, 10]. Medicinal plants are well-known for therapeutically active phytochemicals, including polyphenols, flavonoids, alkaloids, terpenoids, etc. Among various medicinal plants, the *Berberidaceae* family has been utilized for the treatment of hypertension, osteoporosis, ocular trachoma, diabetes mellitus, cardiovascular ailments, jaundice, bone fractures, spleen enlargement, eye troubles, digestive complaints, infectious diseases (cholera, dysentery, diarrhea, giardiasis, etc.) and cancer [11]. *Berberis lycium* from this family has been extensively used in Homeopathic, Unani, Eastern, Ayurvedic, and Modern systems of medicine [12]. *Berberis Lycium* contains rich reserves of phytonutrients such as steroids, alkaloids, flavonoids, triterpenoids, and glycosides [13]. Literature has shown multiple pharmacological properties of *Berberis* including cholesterol-lowering, antipyretic, inflammatory, antidiabetic, anticancer, antioxidant, antibacterial, antihypertensive, and antiviral potential [11–14].

Furthermore, the potential use of *Berberis lycium* in neuropsychiatric conditions was investigated [15], and the results presented that the presence of alkaloids in *Berberis lycium* affected L-arginine-NO-cGMP signaling pathway to produce antidepressant activity [15, 16]. Moreover, it has been reported that *Berberis lycium* exhibits no adverse effects on animal or human health [11].

Several investigations have been executed on neuroprotective effects of *Berberis* species including *Berberis aristata* and *Berberis vulgaris* [11]. Since, there is presently no reliable cure available for AD; therefore, the major challenge is the development of efficacious drugs and therapies to prevent and cure AD. Considering the role of neurotransmitters, a drug/compound that may increase the level of these neurotransmitters can be a potential cure for AD. There is limited data on neuroprotective effect of *Berberis lyceum*. Hence, this study was designed to investigate neuroprotective role of *Berberis lyceum*. It was hypothesized that bioactive compound/s isolated via bioassay guided method from crude extract of *Berberis lycium* might be effective for treating AD. For this purpose, aluminium chloride induced Alzheimer's disease rat model was used. Aluminium has been reported as a significant risk factor for the cause and development of AD, amyotrophic lateral sclerosis, and Parkinson's disease (PD). Aluminium establishes disturbances in cholinergic neurotransmission, which may be associated with altered memory and learning processes in AD patients [17]. The rationale behind using rats is that they mimic aspects of a biological process or disease found in humans and researchers can extrapolate the results of animal model studies to better understand human physiology and disease. In the present study, we report significant effect of berberine isolated from *Berberis lyceum* in Alzheimer's diseases model via inhibiting acetylcholinesterase activity, improving memory and performance and increasing neurotransmitter levels.

Materials & methods

Chemicals

Methanol, chloroform, dimethylsulfoxide (DMSO), potassium phosphate, acetylcholine substrate and galantamine hydrochloride were obtained from Sigma Aldrich. All chemicals and solvents were purchased from Sigma Aldrich (USA) unless otherwise stated.

Plant collection, extraction and fractionation

The plant (*Berberis lycium*) was collected from the Abbottabad (34°92'N, 73°13'E), Khyber Pakhtunkhwa, Pakistan and was identified (specimen voucher number PHM-521) by Prof. Dr. Mushtaq Ahmad, Department of Plant Sciences, Quaid-i-Azam University, Islamabad, Pakistan. The plant materials were separated, shade dried, crushed, and macerated in mixture of methanol and chloroform (1:1) for 7 days. Then it was concentrated by rotary evaporator (Buchi Rotavapor R-200, Switzerland) to obtain the crude extract [18]. The crude extract was then fractionated using n-hexane, ethyl acetate, methanol, and water. All fractions were filtered, dried, and stored at -20°C until further use. Different fractions were named as stem (S-Hex: stem n-hexane, S-EA: stem ethyl acetate, S-Me: stem methanol, and S-Aq: stem aqueous), leaf (L-Hex: leaf n-hexane, L-EA: leaf ethyl acetate, L-Me: leaf methanol and L-Aq: leaf aqueous) and root (R-Hex: root n-hexane, R-EA: root ethyl acetate, R-Me: root methanol, R-Aq: root aqueous) extracts.

Acetylcholinesterase inhibitory activities

All extracts were tested for their potential acetylcholinesterase inhibitory activity as reported earlier [19]. For the experiment, 50 µl of potassium phosphate buffer (pH 8, 0.1 M), 25 µl of the enzyme (0.01 U), 125 µl of DTNB (3 mM), 25 µl of acetylcholine substrate (15 mM), and

25 µl of the sample with final concentration 100 mg/ml were mixed in 96-well plates. Plates were then incubated for 30 min at 37°C. The experiments were performed in triplicate using DMSO and galantamine hydrobromide as negative and positive controls, respectively. Enzyme inhibition activity was calculated using the formula:

$$\% \text{ inhibition} = (Ac - As / Ac) \times 100,$$

where Ac is the change in absorbance for the control and As is the change in absorbance for the sample measured with a microplate reader (Elx 800) at 405 nm.

Bioassays guided isolation. Depending upon the results from the initial screening of acetylcholinesterase activity of different crude extracts, roots extract was selected for bioassay guided isolation.

Purification of berberine using preparative liquid chromatography. Berberine was isolated from the root extract of *Berberis lyceum* prepared by maceration in methanol. Precisely weighed 250 g of extract was packed in preparative glass column (800 mm × 110 mm) fitted with Shimadzu LC-8A pump. The sample was adsorbed on silica gel (70–230 mesh, Merck, Germany) and loaded on the column. The column was attached with the chromatography system and eluted with gradient mobile phase starting with ethyl acetate (mobile phase A) and ending with methanol (mobile phase B) with linear gradient from 1–120 minutes with flow rate of 50 ml per minutes. Each fraction after 3 minutes (150 ml) was separated and evaporated under reduced pressure and 37th fraction (EAM37) yielded berberine in the form of yellow precipitates (5 g). Further purity testing of berberine was analyzed through analytical HPLC.

Qualitative phytochemical analysis. Qualitative analysis of EAM37 and related fractions were performed using the previously reported methodology [20], and a brief description of each method is given below.

Alkaloids: For the alkaloid test, 0.4 g of samples were mixed with 1% (v/v) hydrogen chloride, boiled, and filtered by Whatman filter paper No. 1. From the filtrate, 200 µl was taken and mixed with Dragendorff's reagent for the presence of alkaloids.

Saponins: Saponins have the characteristic feature to produce emulsion when mixed with oil. This feature is used for qualitative test of saponins. For the experiment, 0.02 g of samples were boiled in 20 ml distilled water for five minutes and filtered with Whatman filter paper No. 1. Then 5 ml distilled water was added to 10 ml of filtrate 10 ml. The mixture was shaken vigorously till the formation of froth, and three drops of olive oil were added to observe the emulsion formation in the mixture.

Terpenoids: Terpenoids in the samples were determined by mixing 5 ml (100 mg/ml) of each sample with 1 ml of chloroform and 2 ml of 100% sulfuric acid. The development of the reddish coloration in the interface reveals the presence of terpenoids.

Anthraquinones: In the anthraquinones assay, 100 mg of samples were boiled with 6 ml of 1% HCl and filtered. The filtrates were then mixed with benzene (5 ml), filtered again, and shaken vigorously with 2 ml of 10% ammonia. The development of pink, red, or violet color indicated the presence of anthraquinones.

Cardiac glycosides: For cardiac glycoside assessment, samples (100 mg/ml) were mixed with glacial acetic acid (2 ml) with one drop of FeCl₃. Then concentrated H₂SO₄ (1 ml) was added to the mixture, and the presence of brownish color interface confirmed the presence of cardiac glycosides.

Coumarins: In the coumarins test, 0.3 g of each sample was taken in the test tube. These test tubes were covered with filter paper moistened with 1 N NaOH. The test tubes were then placed in a water bath for 10 min. After that, the filter paper was removed and visualized under UV for the presence of coumarins.

Phlobatannins: For detection of phlobatannins, 100 mg of each sample was heated with 1% (v/v) HCl, and the presence of phlobatannins was confirmed by the formation of the red precipitate.

Flavonoids: Flavonoids in samples were detected by mixing 20 mg of each sample in 50 ml of distilled water and 5 ml of diluted ammonia. The development of yellow color confirmed the presence of flavonoids after adding a few drops of concentrated H_2SO_4 .

Tannins: In tannins, 0.05 g of each sample was heated in 20 ml distilled H_2O (20 ml), and then a few drops of 0.1% FeCl_3 were added. Tannin's presence was confirmed by the appearance of blue-black or brownish green color.

Thin layer chromatography (TLC) analysis. For the identification of EAM37 precipitates, the TLC method was developed using different mobile phases and detection reagents. TLC silica gel 60 F₂₅₄ TLC plates (20 × 20 cm, Merck, Germany) were cut into pieces (6.6 cm × 3.8 cm). Each TLC piece plate was marked at a distance of 1 cm from the bottom with a graphite pencil. An equal amount of each sample/ standard (0.5 μl) was loaded with a micropipette at an equal distance on the marked line and allowed to dry. TLC was performed with the laboratory available alkaloids standards, including morphine, quinine, scopolamine, caffeine, and berberine. Then these TLCs were developed in different combinations of mobile phase (15 ml) in a TLC tank. After development, TLC plates were allowed to dry and were visualized for active compounds under 254 nm and 356 nm wavelengths. Later, the TLC plates were stained with Dragendorff reagent to detect alkaloids.

High-performance liquid chromatography (HPLC) analysis. The analytical HPLC method was used to confirm EAM37 as an alkaloid. For this confirmation, laboratory standards, including morphine, quinine, scopolamine, caffeine, and berberine, were run on HPLC along with EAM37 using the previously reported method [21]. The analysis was carried out using HPLC-DAD equipment (Agilent Germany) using a C18 analytical column (5 μm particle size, 4.6 × 250 mm). During analysis, mobile phase A was prepared by mixing HPLC grade acetonitrile, water, methanol, and acetic acid with ratios of 5:85:10:1. In contrast, mobile phase B was prepared by mixing HPLC grade acetic acid, acetonitrile, and methanol with ratios 1:40:60. These mobile phases were used as gradient program operated by HPLC software following 0 to 50% B between 0–10 min, 50 to 100% B between 10–15 min, and isocratic 100% B between 15–20 min. Additionally, before each analysis the column was reconditioned for 10 min. Finally, identification was carried out by analyzing the graphs of standards and samples.

FTIR analysis. FTIR analysis was performed for the confirmation of isolated sample as berberine using reported method by Sherazi et al. [22]. For this purpose, root extract of B. lyceum, isolated berberine and commercial berberine was analyzed using the Nicolet S5 FT-IR spectrometer (Thermo Scientific, USA) provided with a 200 Km KCl transfer cell and iD7 ATR. Analysis was performed in triplicate and spectra were collected on the Mid IR scale of 4000–400 cm^{-1} goal of 4 cm^{-1} .

NMR analysis. ^1H and ^{13}C NMR analysis was performed to ascertain the purity of the isolated compound. The resulting spectra was compared and confirmed with the data reported in the previous literature. Both types of 1D spectroscopy was performed using Bruker Avance III HD 400 MHz. Chemical shifts were calculated in parts per million (ppm) whereas coupling constant (J) was calculated in Hertz (Hz).

In vivo anti-Alzheimer's disease activity of the isolated compound. Sprague-Dawley male rats weighing 200–220 g (nine weeks) were used in the experiment. Animals were obtained from the National Institute of Health, Pakistan. Animals were previously healthy and were not utilized in any experiment before. The rats were placed in cages with 12/12 light-dark cycles, proper sanitary conditions, and access to food and water *ad libitum*. All experiments were approved by the Institutional Biosafety Committee (IBC), University of Gujrat, Pakistan,

under approval number 318. Additionally, National Institute of Health (NIH) Pakistan guidelines were followed to ensure minimal animal suffering. This study used 30 rats with five in each group. The following order of dosage was maintained in all experiments, and all doses were given orally on alternate days for 21 days. Rats were divided into normal control (received only 0.9% saline), Alzheimer's disease (AlzDis) control received AlCl_3 (100 mg/kg) and Alzheimer's disease's positive (AlzPC) control received 10 mg/kg Rivastigmine+ AlCl_3 (100 mg/kg), while berberine treated groups received 20, 10 and 5 mg/kg of berberine+ AlCl_3 (100 mg/kg). The sample size was decided as per OECD guidelines. In this study, no randomization and exclusion criteria were used. Additionally, the participants were blinded about the group allocation during experiments, and data analysis.

Acute oral toxicity. For acute oral toxicity study, a single dose of isolated berberine (100 mg/kg) was administered orally to a group of five rats as per OECD guidelines #425 [23]. The normal control group received normal saline (oral; 10 ml/kg). Any behavioral changes and toxicity or mortality as per OECD guidelines #425 were observed for up to one week.

Behavioral studies. *Elevated plus maze (EPM) test.* The standard EPM model was used to check the effect of berberine on anxiety-like behavior of rats as reported previously [24]. Briefly, an A-plus shaped platform with two closed sides and two open sides was used. Each rat was placed in the center facing toward the open arm and movement in the maze was recorded for 5 min with the help of a mounted camera. After the experiments, rats were cleaned and returned to their home cages. Time spent in closed and open spaces was calculated using ANY-maze software (Stoelting Co., USA). The experiment was performed in triplicate. At the end of the test, the maze was cleaned with 70% ethanol.

Morris water maze (MWM) test. The memory patterns in rats after berberine treatment were evaluated by standard MWM model as reported earlier [24]. The protocol involved 1 visible and 2 hidden day trials and a single probe trial at the end of hidden trial. During visible trials, the platform was 1 cm above the water surface, and rats were placed in all quadrants until they reached the platform. In hidden trials, the platform was under water, and some dye was added to make the platform invisible. The platform was placed in different quadrants, and rats were released from all positions to reach the platform. A single probe trial of 60 sec was recorded for each visible and hidden trial at an interval of 1 h with the help of the mounted camera. The experiment was performed in triplicate. ANY-maze video-tracking system was used to analyze the movements of rats in the maze [25].

Dissection, tissue collection, and antioxidant activity determination

After completion of experiments, rats were euthanized with isoflurane (5%) and dissected using OECD guidelines. For euthanasia, it was ensured that rats completely lose consciousness, and death is caused without pain. Next, brain tissues were dissected and stored in saline (0.9%). For enzyme estimation, brain tissues were homogenized in ice-cold 50 mM tris buffer at pH 7.4 followed by centrifugation [26]. The obtained homogenate was used for the estimation of catalase (CAT) [27], peroxidase (POD), glutathione (GHS) [28], superoxide dismutase (SOD) [29], thiobarbituric acid reactive species (TBARS) [30], and total proteins [31].

Determination of neurotransmitters

Complete rat brain was dissected, washed with cold saline and stored at -70°C until estimation of neurotransmitters, i.e., dopamine and serotonin. For neurotransmitter analysis, tissues were homogenized in phosphate buffer and centrifuged at 14000 rpm for 10 min at 4°C . After centrifugation, the supernatant was filtered by a syringe filter (0.2 μm), and 20 μl of the sample was injected into the Agilent HPLC-1200. Isocratic mobile phase of 50 mM potassium

phosphate buffer in 3% methanol was used for analysis. The flow rate was adjusted to 1.5 ml/min with total run time of 25 min. HPLC separation was carried out using a C18 (5 μ m $\times$ 250 mm $\times$ 4.6 mm) column and detected at 270nm by a UV detector. Experiments were performed in triplicate. Neurotransmitter levels were quantified using standard linear regression equations [18, 24].

Western blot analysis

Brain samples of rats from berberine treated, AlzPC, and AlzDis groups were harvested and flash frozen at -80°C. Samples were lysed using ice-cold RIPA buffer and homogenized using a handheld homogenizer (Fisherbrand™). After centrifugation, the supernatant was separated, and proteins were quantified using a BCA protein assay kit. About 50 μ g of protein was separated using self-casted polyacrylamide gel and transferred to 0.2 μ m nitrocellulose membrane. The blot was washed, blocked with blocking buffer, and probed with β -secretase primary (Anti-BACE (D10E5); Cat#5606T; Dilution 1:3000) and anti-rabbit horseradish peroxidase-conjugated secondary antibodies (Beverly, MA; Dilution 1:1000). The blots were detected using omniDOC gel documentation system (Cleaver Scientific; UK). The resulting blots were enhanced using Adobe Photoshop for brightness and contrast for uniformity of appearance. Densitometry analysis was performed using ImageJ software and plotted by GraphPad Prism after normalizing to vinculin [31, 32]. The analysis was repeated thrice and one blot was selected to present the data.

Docking of berberine over β -secretase

Berberine was docked over β -secretase to find their possible interaction. For docking purposes, receptor β -secretase was downloaded from the PDB site with reference number 2OHP, and the structure of ligand berberine (CID 2353) and Rivastigmine (CID 77991) was downloaded from PubChem. Receptor and ligand files were prepared by software BIOVIA DISCOVERY STUDIO Client 2020 and MGL Tools 1.5.6 and were saved as PDBQT files. The docking was performed via AUTODOCK VINA as reported earlier [33]. The dimensions for grid size at x, y and z axis was 26 each with spacing of 1 Angstrom. The results were analyzed by PyMOL, where binding residues and bond lengths were noted.

ADMET analysis

Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. A potent molecule must reach its target in the body in sufficient concentration and remain there in a bioactive state long enough for the anticipated biologic events to occur in order to be effective as a drug. For this purpose, ADMET analysis for berberine and Rivastigmine were determined by SWISSADME online server [34]. The canonical structures for analysis were obtained from PubChem.

Molecular dynamic simulation

The protein ligand complex after docking was analyzed for molecular dynamic simulations where the binding interaction stability was evaluated. Gromacs under linux system was used for simulations analysis [35]. CHARMM36 force fields jul2021 version from MacKerell Lab was used [36]. The analysis was performed for 10 ns with 500000 steps. The protein ligand docked complex of secretase with berberine and Rivastigmine was evaluated for stability of complex by calculating the RMSD and radius of gyration characteristics.

Statistical analysis

All data were expressed as the mean $\pm$ SD with statistical differences ($p < 0.05$) between groups using ANOVA. Before analysis, data were tested for normality and equality of variance. Data was also tested for the presence of any outlier. Statistical analysis was performed using Graph-Pad Prism 8.1 software.

Results and discussion

Berberis lycium root extracts significantly inhibit acetylcholinesterase *in vitro*

Currently, acetylcholinesterase is the major enzyme being explored for treating neurological illnesses such as AD, senile dementia, ataxia, and myasthenia gravis [37]. In this study, the microplate-based method determined the acetylcholinesterase inhibition potential of the stem, leaves, and root fractions of *Berberis lycium* at a concentration of 100 mg/ml. Experiments were performed in triplicate, and the results are presented in Fig 1. The highest percentage of inhibition was revealed in methanolic root extract (R-Me: 63.96%), while methanolic extracts of stem and leaves exhibited 21.26% and 21.62% inhibition, respectively. Positive control showed 92.25% inhibition, while no activity was recorded for n-hexane and ethyl acetate extracts and fractions. So, we proceeded with the R-Me fraction for bioassay guided isolation of natural compound/s.

Isolation of berberine from roots of *Berberis lycium*

Since, the extracts of stem and leaves exhibited negligible acetylcholinesterase inhibitory activity as compared to root extract; hence, the root extract was selected for bioassay guided isolation of anti-Alzheimer's compound using column chromatography. During the elution




Fig 1. Acetylcholinesterase inhibition activity of stem, leaf and root fractions. Acetylcholinesterase inhibition activity was determined by measuring the change in absorbance of control and sample treated reaction mixtures. Values are expressed as mean ($n = 3$) $\pm$ SD of percent inhibition of acetylcholinesterase. S = stem, L = leaf, R = root, Hex = n-hexane, EA = ethyl acetate, Me = methanol, Aq = aqueous and Gal-Hy = galantamine hydrobromide (positive control). Here *** $p < 0.001$ with respect to galantamine hydrobromide.

<https://doi.org/10.1371/journal.pone.0286349.g001>

Table 1. Acetylcholinesterase inhibition activity of isolated fraction.

Sample	Percentage inhibition $\pm$ Standard deviation			IC50 mg/ml
	200 mg/ml	100 mg/ml	50 mg/ml	
EAM37 fraction	75.04 $\pm$ 0.29***	37.29 $\pm$ 1.95***	5.58 $\pm$ 1.36***	126.70 $\pm$ 2.54***
Galantamine hydrobromide	92.64 $\pm$ 0.30	87.18 $\pm$ 0.51	80.17 $\pm$ 0.30	8.79 $\pm$ 1.02

Values are expressed as mean (n = 3) $\pm$ SD where ***p<0.001 with respect to galantamine hydrobromide.

<https://doi.org/10.1371/journal.pone.0286349.t001>

process with mixture of ethyl acetate and methanol, yellow precipitates were formed in a fraction collected from the mobile phase having a ratio of 3:7. This fraction was named EAM37 and was re-evaluated for acetylcholinesterase inhibition potential. Results displayed prominent acetylcholinesterase inhibitory activity (75.04%) as presented in Table 1. Acetylcholinesterase is the most important neurotransmitter involved in the control of cognitive activities in the central cholinergic system. Cholinergic neuronal loss in the hippocampal area is a prominent hallmark of AD, and anticholinesterase treatment is currently used for its therapy [38]. Search for plant-derived acetylcholinesterase inhibitors has been accelerated due to their benefits in treating AD as well as vascular dementia and dementia with Lewy bodies [39]. Compounds like huperzine-A, galantamine, viniferin, and ursolic acid that are derived from *Huperzia serrata*, *Galanthus nivalis*, *Narcissus sp.*, *Caragana chamlague*, and *Origanum majorana*, respectively, have exhibited relatively significant anticholinesterase action [37]. These studies provide the rationale for searching anti-AD treatment from plant sources.

EAM37 was tested positive as an alkaloid

Next, different qualitative phytochemical tests were performed to identify the biochemical nature of EAM37. Results showed that EAM37 was positive for alkaloids while negative for the rest of the tested phytochemicals (Table 2). Our results are in line with the literature, where the majority of anticholinesterases has been testified as alkaloids such as physostigmine and galantamine [37]. Moreover, plants belonging to more than 30 families are reported to have acetylcholinesterase inhibitory potential, where the activity is attributed to over 35 alkaloids [37]. *In vivo* investigations have revealed that treatment with the alkaloid physostigmine, an acetylcholinesterase inhibitor isolated from *P. venenosum*, improves animal cognitive performance. Physostigmine has also been demonstrated to offer significant cognitive improvements in normal and AD patients. However, its practical application may be limited due to its short half-life, which requires daily dosing [37]. In short, there is still a need for plant-based efficient,

Table 2. Phytochemical analysis of EAM37 fraction.

Phytochemical name	Result
Alkaloids	Positive
Saponins	Negative
Terpenoids	Negative
Anthraquinones	Negative
Cardiac glycosides	Negative
Coumarins	Negative
Phlobatannins	Negative
Flavonoids	Negative
Tannins	Negative

<https://doi.org/10.1371/journal.pone.0286349.t002>

long-lasting therapeutics for AD prevention and cure. The isolated compound EAM37 can serve the purpose and may prove effective in treating AD after thorough investigations.

EAM37 was confirmed as berberine by TLC and HPLC

EAM37 fraction was analytically analyzed by TLC and HPLC using available laboratory standards of alkaloids, including morphine, quinine, scopolamine, caffeine, and berberine. EAM37 and selected alkaloid standards in TLC were compared by their R_f values (Fig 2A–2C). Spots marked with graphite pencil were visible with Dragendorff (Fig 2A) reagent. These TLC plates were further visualized at 254 nm (Fig 2B) and 365 nm (Fig 2C) wavelengths for three-fold conformation. On the other hand, HPLC analysis of the EAM37 fraction is presented in Fig 2D. After comparing with the standard (Fig 2E), it was established that the EAM37 fraction was berberine. Hence, it was confirmed that the isolated compound (EAM37) was berberine from TLC and HPLC. Finally, the structure of berberine is presented in (Fig 2F).

Berberine is a natural benzylisoquinolin alkaloid found in *Hydrastis*, *Berberis*, *Thalictrum*, *Mahonia* and *Coptis* genera. Berberine has various pharmacological activities, including anti-inflammatory, antidiarrheal, antibacterial, antiprotozoal, antitrichoma, antimalarial, and anti-cancer properties [40, 41]. Recent studies have revealed that berberine has anticholinesterase, anti-amyloidogenic, anti-tau, and antioxidant properties [41]. Identification of EAM37 as berberine supports its acetylcholinesterase inhibition activity, which is evident from our results. Berberine has been found to increase acetylcholine levels in the streptozotocin-induced sporadic Alzheimer's disease model and scopolamine-induced memory loss and neuronal damage by decreasing acetylcholinesterase activity [42]. Moreover, berberine isolated from *Chelidonium majus* is reported to have dose-dependent acetylcholinesterase inhibitory action [43]. Another study reported increased expression of $\alpha 7$ nAChR in berberine treated insulin resistance mouse model. Reduced $\alpha 7$ nAChR density induces neuroinflammation in cognitively critical brain parts like the hippocampus, and berberine has reversal effects. As a result, it is concluded that berberine boosts acetylcholine levels by blocking its breakdown and extending its duration of action [43].

Since, current AD therapies focus on the combination of cholinergic inhibition, effects on the amyloid cascade, and tau protein; therefore, compounds with both effects will be beneficial [40]. Natural compounds may once again be the source of novel therapeutics or even prototypes for drug development. Here, our work provides useful insight into the effectiveness of berberine.

Confirmation of berberine by FTIR and NMR

The presence of berberine was confirmed using FTIR and NMR analysis and results are presented in Fig 3. In FTIR, Nicolet iS5 FT-IR spectrometer within mid IR range of 4000–400 cm^{-1} was used to compare the isolated berberine with commercial berberine along with crude root extract of *B. lyceum* and FTIR graph is presented in Fig 3A. Following graphs in Fig 3A shows berberine confirmation peaks at 2,844 cm^{-1} and 1635 cm^{-1} in both commercial as well as isolated berberine. These peaks are also reported in literature as 2,844 cm^{-1} peak correspond to methoxyl group while 1635 cm^{-1} peak correspond to iminium ($\text{C} = \text{N}^+$) double bond [44]. The peak at 1023 cm^{-1} represents C-O stretching and peak in the range of 1405–1436 cm^{-1} represents C-H deformation stretching [45]. The Fig 3A also demonstrate that all of the major absorption peaks of commercial berberine, including those at 609, 665, 697, 758, 822, 953, 1023, 1310, 1405, 1436 and 2936 cm^{-1} , are also present in the spectrum of isolated berberine. This gives us confidence that the isolated compound is berberine.




Fig 2. Analysis of isolated compound. [A–C] Thin layer chromatography (TLC) of isolated compound (berberine/EAM37) in comparison with berberine standard. In TLC plates, pencil mark no.1 represents the berberine standard, while marks from no. 2 to no. 8 represent the fractions with yellow precipitates. Plates were visualized [A] in Dragendorff reagent, [B] at 365 nm and [C] at 254 nm. [D & E] EAM37 fraction (berberine) [D] was subjected to HPLC analysis using berberine [E] as standard, and retention time, peak area and height were calculated for confirmation and quantification. [F] structure of berberine.

<https://doi.org/10.1371/journal.pone.0286349.g002>

The 1D NMR analyses revealed the isolation of pure compound. Both ^1H and ^{13}C spectra have been presented in Fig 3B and 3C respectively. The ^1H NMR (DMSO- d_6 , 400 MHz) spectrum showed the presence of protons associated with methoxy groups at position 8 and 9 at




Fig 3. Confirmation of berberine by FTIR and NMR. [A] FTIR graph of isolated berberine (green peak) in comparison with commercial berberine (orange peak) along with root extract of *B. lyceum* (green peak). [B] ^1H NMR (DMSO- d_6 , 400 MHz) spectrum. [C] ^{13}C NMR (DMSO- d_6 , 400 MHz) spectrum.

<https://doi.org/10.1371/journal.pone.0286349.g003>

4.05 ppm (3H, s) and 4.08 ppm (3H, s). The close association of OCH_3 at position 9 with neighboring electronegative N atom in quinolizinium ring led to its deshielding with respect to protons attached to position 8. The most deshielded signal at δH 9.9 (1H, s, H-6), is the typical signal of methine proton. Remaining peaks labels, assigned to respective protons, have been presented in Table 3. Protons at position 10 and 11 were in down field vicinity due to

Table 3. Comparison of NMR peaks of berberine.

Position	δ_H		δ_C	
	Experimental	Reported	Experimental	Reported
1	7.07 s (1H)	7.0 s	108.8	110.0
2			131.1	132.0
3	3.19 t (1H, $J = 6$)	3.20 t	26.7	27.5
4	4.93 t (1H, $J = 6$)	4.90 t	55.6	56.0
6	9.90 s (1H)	9.90 s	145.9	145.0
7			120.9	122.0
8			144.0	143.0
9			150.2	150.0
10	7.98 d (1H, $J = 9$)	7.90 d	124.0	125.0
11	8.18 d (1H, $J = 9$)	8.10 d	127.1	128.0
12			133.4	134.0
13	7.78 s (1H)	7.70 s	105.9	107.0
14			137.9	139.0
15			121.8	123.0
16	8.95 s (1H)	8.90 s	120.6	121.0
17			148.1	148.0
18			150.8	151.0
8-OCH ₃	4.05 s (3H)	4.0 s	57.5	57.0
9-OCH ₃	4.08 s (3H)	4.0 s	62.3	62.0

Chemical shift values have been presented in parts per million (ppm). J (coupling constant) has been calculated in Hz.

<https://doi.org/10.1371/journal.pone.0286349.t003>

their presence near to O atoms in dioxolane ring [46]. The ^{13}C spectrum showed the presence of twenty carbons in isolated compound. A comprehensive and comparative analysis of the identified peaks with the reference data is presented in Table 3. According to the spectroscopic data and previous literature [47] isolated compound was confirmed as berberine.

Berberine showed no significant toxicity in animals

After the high dose treatment of berberine, results showed no significant changes in gross anatomy or overall characteristics of animals during the one week of observation. Moreover, no notable behavioral changes, as well as mortality, were recorded in berberine treated rats as compared with normal control (saline) rats. The present study acknowledges the limitations that the histological presentations of the vital organs and whole blood profiles were not performed. They should be essentially investigated in the future to validate the acute oral toxicity profiles.

Behavioral studies

Berberine inhibits anxiety in AlzDis rats. The anxiolytic effect of berberine was evaluated using the EPM test, and the results are presented in Table 4. Overall, berberine exhibited significant activity in a concentration-dependent manner. Rats treated with 20 mg/kg of berberine presented 3.8 ± 0.84 entries in the open arm (2.3-fold decrease) and 3.0 ± 0.71 entries in the closed arm (3.1-fold reduction) as compared to AlzDis. Similarly, distance traveled in open and closed arms was recorded as 4.865 ± 0.305 m and 0.606 ± 0.206 m, respectively, in rats treated with 20 mg/kg of berberine. In AlzDis, distance traveled in the open and closed arm was recorded as 4.53 ± 0.50 m and 2.33 ± 0.7 m, while in the normal control (saline) group,

Table 4. Number of entries and distance travelled in elevated plus maze test.

Groups	Number of entries in open arm	Number of entries in closed arm	Distance travelled in open arm (m)	Distance travelled in closed arm (m)
Normal Control	3.40±1.14	3.20±0.84	4.59±0.39	1.94±0.51
Alzheimer's Control (AlzDis)	9.00±1.00***	9.40±1.14***	2.33±0.78***	4.53±0.50***
Rivastigmine 10 mg/kg (AlzPC)	5.00±1.00***	7.00±1.00****	3.87±0.87 ^{NS}	3.16±0.92**
Berberine 5 mg/kg	9.20±0.84***	8.20±0.84***	3.19±0.09***	3.54±0.34***
Berberine 10 mg/kg	6.00±0.71***	5.20±0.84**	3.61±0.22*	2.92±0.05*
Berberine 20 mg/kg	3.80±0.84 ^{NS}	3.00±0.71 ^{NS}	4.86±0.31 ^{NS}	0.61±0.21***

Values are expressed as mean (n = 3) ± SD where ***p<0.001

**p<0.01

*p<0.05

and NS is non-significant with respect to normal control.

<https://doi.org/10.1371/journal.pone.0286349.t004>

distance traveled in the closed arm recorded as 1.9±0.51 m and 4.60±0.39 m for an open arm. A study on berberine presented similar results in which morphine-dependent rats showed the decreased percentage of open arm distance and entries. In the same study, administration of 50 mg/kg of berberine indicated significant increase (17%) in open arm activity [42]. These results are in accordance with our present findings, which indicate that the berberine treated rats show lower signs of anxiety as compared to AlzDis rats.

Berberine improved memory pattern in AlzDis rats. The memory pattern in rats after berberine treatment was determined using the MWM test, and the results are presented in Table 5. The experiments were performed in triplicate using visible and hidden trails. For visible trial, the berberine treated group at 20 mg/kg showed 1.93-fold higher activity by reaching the platform in 11.16±0.82 sec as compared to the AlzDis group. Likewise, in the hidden trial, the berberine treated group at 20 mg/kg demonstrated 1.56-fold improvement by reaching the platform in 20.66±0.65 sec as compared to the AlzDis group. Additionally, rats spent more time on close platform and latency time was recorded at lower rates in berberine treated rats compared to AlzDis rats. Overall, an improved memory pattern was observed after berberine treatment in the concentration-dependent manner. In literature, a study on APP^{NL-G-F} rats

Table 5. Visible and hidden trails, latency time, total time spend in Morris water maze test.

Groups	Time required in visible trial (sec)	Time required in hidden trial (sec)	Time spent in platform zone (sec)	Latency time to reach platform zone (sec)
Normal Control	8.12±1.73	17.00±1.69	55.30±1.54	3.36±0.63
Alzheimer's Control (AlzDis)	21.56±1.95***	32.14±1.49***	26.96±2.89***	27.62±1.66***
Rivastigmine 10 mg/kg (AlzPC)	15.72±1.88***	19.40±1.31*	53.36±0.63 ^{NS}	3.10±0.41 ^{NS}
Berberine 5 mg/kg	20.54±0.50***	31.24±0.55***	38.30±1.34***	12.8±0.59***
Berberine 10 mg/kg	17.66±0.69***	25.66±0.63***	45.92±1.01***	7.46±0.46***
Berberine 20 mg/kg	11.16±0.82**	20.66±0.65***	51.34±1.27**	4.48±0.48 ^{NS}

Values are expressed as mean (n = 3) ± SD where ***p<0.001

**p<0.01

*p<0.05

and NS is non-significant with respect to normal control.

<https://doi.org/10.1371/journal.pone.0286349.t005>

showed memory retention in a probe trial where the time spent in the platform zone quadrant was significantly higher [48]. In another study, berberine at concentration of 50 mg/kg significantly improved the memory and spatial behavior in chronic cerebral hypoperfusion rats by spending more time platform zone [49]. In short, berberine showed improvement in memory of diseased rats.

Berberine reduced oxidative stress in AlzDis rats

Levels of POD, GSH, TBARS, CAT and SOD were calculated, and the results are presented in Table 6. It was found that berberine showed significant antioxidant activities in a concentration-dependent manner. It was recorded that all elevated enzymes were restored to their normal state in berberine treated rats when compared with the AlzDis group and normal control (saline 0.9%) group (Table 6). Berberine is an efficient antioxidant exhibiting peroxynitrite scavenging activity, ROS inhibitory capability and TBARS reduction [50, 51]. SOD-1 and SOD-2 genes associated with superoxide dismutase enzymes are disrupted or mutated in neurodegenerative diseases like AD. The SOD-1 deficiency in an AD model showed memory impairment by oxidative stress [52]. Berberine restored antioxidant enzyme levels in AlzDis rats indicating its effectiveness in ameliorating oxidative stress mediated neurodegeneration.

Berberine restored neurotransmitters levels in brain samples

In AD, dopamine has been intensively recounted as a critical neurotransmitter involved with emotion and cognition [53]. Dopamine acts through five different receptors, including D1R, D2R, D3R, D4R and D5R [54]. These receptors are expressed in different regions of the brain, which control mood and emotional stability. Literature showed that dopamine acts through D2R to increase cortical excitability and D1R to augment the release of cortical acetylcholine [54]. Serotonin plays a significant role in memory retention and learning. Like dopamine, serotonin also acts through specific receptors located in the brain [55]. Serotonin stimulation via receptor 5-HT_{2A/2C} or 5-HT₄ and serotonin inhibition via receptors 5-HT_{1A}, 5-HT₃ or 5-HT_{1B} receptors lead to memory and learning impairment under conditions of high cognitive demand [55]. Additionally, activation of serotonin receptors decreases A β production and levels in brain and enhances neuronal survival in AD patients [56]. In this study, levels of

Table 6. Status of antioxidant enzymes in brain homogenates.

Groups	Protein estimation (ug/mg tissue)	POD (U/min)	GSH (mM/g tissue)	TBARS (nM/min/mg tissue)	CAT (U/min)	SOD (u/min)
Normal Control	2.661±0.003	0.081±0.171	0.088±0.014	0.007±0.005	4.468±0.157	1.534±0.131
Alzheimer's Control (AlzDis)	6.384±0.042	0.155 ±0.074***	0.212±0.031***	0.019±0.017***	2.540 ±0.493***	0.566±0.114***
Rivastigmine 10 mg/kg (AlzPC)	2.649±0.076	0.067±0.162 ^{NS}	0.083±0.055 ^{NS}	0.006±0.020 ^{NS}	3.724±0.315**	0.858±0.436**
Berberine 5 mg/kg	5.496±0.003	0.154 ±0.015***	0.208±0.038***	0.018±0.002***	2.503 ±0.002***	0.560 ±0.0005***
Berberine 10 mg/kg	3.321±0.004	0.121 ±0.053***	0.133±0.069***	0.012±0.004***	2.045 ±0.002***	0.476 ±0.0005***
Berberine 20 mg/kg	2.384±0.004	0.061±0.049 ^{NS}	0.078±0.061 ^{NS}	0.007±0.002 ^{NS}	4.347±0.003 ^{NS}	1.396±0.0005 ^{NS}

Values are expressed as mean (n = 3) ± SD where

***p<0.001

**p<0.01

and NS is non-significant with respect to normal control.

<https://doi.org/10.1371/journal.pone.0286349.t006>




Fig 4. Quantification of neurotransmitters in rat's complete brain tissue. The levels of dopamine and serotonin in brain tissues of normal control and diseased rats treated with berberine (5, 10, 20 mg/kg) and Rivastigmine-AlzPC (10 mg/kg). The bars for Alzheimer's disease (AlzDis) group are not shown since the values were 0.002 μ g/mg and 0.004 μ g/mg for dopamine and serotonin, respectively. The values are too low to appear as bars. Values are expressed as mean ($n = 3$) $\pm$ SD where *** $p < 0.001$, * $p < 0.05$ with respect to normal control.

<https://doi.org/10.1371/journal.pone.0286349.g004>

dopamine and serotonin were determined by HPLC and results are presented in Fig 4. Results showed that the highest level of dopamine and serotonin were observed at 20 mg/kg dose of berberine. There was moderate elevation of neurotransmitters at 10 mg/kg dose of berberine. However, not activity was exhibited at 5 mg/kg dose of berberine. In AlzDis group, the levels of dopamine and serotonin were calculated as 0.002 and 0.004 μ g/mg of tissue, respectively. On the contrary, 0.82 μ g/mg of dopamine and 1.04 μ g/mg serotonin were detected in normal control group (Fig 4). Rivastigmine was used in the AlzPC group, which exhibited 1.4 μ g/mg of dopamine and 1.8 μ g/mg of serotonin. A study on AD in transgenic TgCRND8 animals indicated a decreased level of dopamine in the hippocampus (427.21 pg/mg) compared to wild type (894.09 pg/mg), suggesting dopaminergic dysfunction [57]. Likewise, another study on APP^{swe}/PS1^{dE9} mice showed a significant decrease in serotonin receptor binding [58]. This decreases the serotonin secretions and disrupts the serotonergic system, thus further progressing AD. In another study, an increase in dopamine (31%) and serotonin (47%) levels were calculated after acute administration of 5 mg/kg berberine in mice [59]. The increase in these biogenic amines can be attributed to berberine's monoamine oxidase enzyme inhibition [60].

Berberine reduced expression of β -secretase

β -secretase is an important enzyme responsible for trimming few proteins necessary for neural activity. It can induce the accumulation of amyloid β peptide by cleaving the extracellular domain of amyloid precursor protein. The greater the activity of β -secretase, the more A β peptide accumulation results, and neuronal cells lead to AD [61]. Studies have shown that

reducing the levels of β -secretase is an important target in treating AD [62]. Since in above mentioned results, berberine at concentrations of 20 mg/kg and 10 mg/kg demonstrated significant results; therefore, the expression of β -secretase was determined at these two concentrations only and results are presented in Fig 5A and 5B (original blots are available at S1 and S2 Figs). It was observed that the 20 mg/kg dose of berberine significantly (30.58% decline; $p < 0.05$) reduced the expression of β -secretase in rat brain lysate. These results were comparable with AlzPC, which reduced the expression of β -secretase by 26.13% compared to AlzDis control normalized to vinculin. Our results are in consensus with the literature, where β -secretase expression was significantly reduced in the hippocampus berberine treated AD mice [63]. Additionally, berberine is known to disrupt the production and aggregation of A β protein in several ways. It inhibits pathogenic A β production and aggregation in human neuroglioma H4 cells by increasing γ -secretase activity and decreasing β -secretase activity [64]. It also inhibits β -secretase production in human embryonic kidney cells [65] and blocks BACE 1 activity [66]. Berberine inhibits kinase (GSK-3b) activation and lowers tau hyperphosphorylation in numerous *in vitro* systems, including HEK293 cells and neuroblastoma-2a cells [67]. This alkaloid is also effective against inflammatory conditions, including the inhibition of IL-6, cyclooxygenase-2, and nitric oxide synthase in primary microglia and murine microglial cells (BV-2) provoked by A β (iNOS). Thus, berberine can be considered a good therapeutic strategy for the management of AD. However, clinical trials have not been carried out extensively. Therefore, more clinical research is required to practice berberine as medicine.

Interaction of berberine with β -secretase

Subsequently, berberine ligand was docked with β -secretase receptor to identify the possible mode of interactions responsible for berberine induced reduced expression of β -secretase (Fig 4C). The drug Rivastigmine used against Alzheimer was also docked with β -secretase. Results depicted a strong interaction of berberine with tyrosine residue (Y-198) of β -secretase with -7.1 kcal/mol bond affinity and 2.0 Å bond length. A polar interaction via H bonding occurs between OH group of tyrosine and O atom of berberine (highlighted in red). Rivastigmine showed interaction with serine residue (S-10) with binding energy of -5.8 kcal/mol and 3.4 Å bond length. It showed polar interaction of serine OH group with Rivastigmine's O atom via H bonding (highlighted in red). Overall, the interaction of β -secretase with berberine was more stable with less energy and low bond length as compared to drug Rivastigmine. Docking results are presented in Table 7. This Tyr198 residue is a component of active site of β -secretase. This aligns with the results of western blotting, where decreased expression of β -secretase in berberine treated rat brains can be due to its interaction with its active site amino acid. Previously, researchers [68] docked the berberine with four enzymes including acetylcholinesterase and butyrylcholinesterase. Theoretically estimated binding constants (K_d) of berberine with acetylcholinesterase and butyrylcholinesterase was estimated as 0.66 μ M and 3.31 μ M respectively. These binding affinities of berberine were very close to the our experimental IC_{50} values 126.7 $\pm$ 2.5 mg/ml with K_d value of 0.44 μ M representing strong interaction of berberine with the enzyme. It was also reported that berberine binds with the active site leading to conformational changes, thus acting as a competitive inhibitor of the enzymes [69]. Our results are in consensus with the literature and have important implications for the berberine based anti-AD drug design.

ADMET analysis

The ADMET analysis of berberine and Rivastigmine indicate that berberine having more weight have high surface area, lipophilicity, accessibility and low solubility compared to




Fig 5. Interaction of berberine with β -secretase. [A & B] Proteins from complete brain samples of AlzDis control, berberine treated and AlzPC were extracted and subjected to western blot analysis for the expression [A] of β -secretase. The experiment was run in triplicate and a representative blot was selected. The blot was adjusted for brightness and contrast for clarity of bands. Vinculin was used as a loading control. C and R represent AlzDis control and Rivastigmine (AlzPC), respectively. Expression was assessed at 10 and 20 mg/kg doses of berberine. [B] Density of the band was analyzed by Image J software and normalized to vinculin. Data were plotted using GraphPad Prism. [C] Docking results of berberine with β -secretase. Fig depicts the interaction of berberine (gray bold lines) with tyrosine residue (pink) of β -secretase with bond length of 2.0 Å (red dotted lines). [D] Docking results of Rivastigmine with β -secretase. Fig depicts the interaction of Rivastigmine (gray bold line) with serine residue (orange) of β -secretase with bond length of 3.4 Å (red dotted lines).

<https://doi.org/10.1371/journal.pone.0286349.g005>

Table 7. Docking interaction of berberine and Rivastigmine with β -secretase.

Ligand	Binding energy	Binding residue	Interaction	Bond length
Berberine	-7.1 kcal/mol	Tyrosine-198	Polar, H bonding	2.0 Å
Rivastigmine	-5.8 kcal/mol	S-10 GLU-339	Polar, H bonding	3.4 Å

<https://doi.org/10.1371/journal.pone.0286349.t007>

Table 8. ADMET analysis of berberine and Rivastigmine.

Molecule	Molecular weight (g/mol)	TPSA ($\text{\AA}^2$)	Lipophilicity Log $P_{o/w}$	Water solubility/ Log S	Synthetic accessibility
Berberine	336.36	40.80	2.53	Moderately soluble/ -5.92	3.14
Rivastigmine	250.34	32.78	2.34	Soluble/ -3.15	2.73

TPSA (topological polar surface area)

<https://doi.org/10.1371/journal.pone.0286349.t008>

Table 9. Pharmacokinetics analysis of berberine and Rivastigmine.

Parameter	Berberine	Rivastigmine
Gastrointestinal absorption	High	High
Blood brain barrier permeant	Yes	Yes
P-glycoprotein substrate	Yes	No
CYP1A2 inhibitor	Yes	No
CYP2C19 inhibitor	No	No
CYP2C9 inhibitor	No	No
CYP2D6 inhibitor	Yes	No
CYP3A4 inhibitor	Yes	No
Skin permeation (log K_p)	-5.78 cm/s	-6.20 cm/s

<https://doi.org/10.1371/journal.pone.0286349.t009>

Rivastigmine. The bioavailability score for both molecules was same 0.55. The results from ADMET analysis are presented in Table 8. Pharmacokinetic analysis is given in Table 9 showing that Rivastigmine is not an inhibitor to any cytochrome complex while berberine shows inhibition against 4 out of 6 complexes with skin penetration effect of -5.78 cm/s.

Molecular dynamic simulation

The graphs for RMSD and radius of gyration for both complexes of secretase with berberine and Rivastigmine are given in Fig 6A and 6B respectively. The graph in Fig 6A shows RMSD results that indicate the stability of complex. The secretase-rivastigmine complex (blue) indicate that it is somehow stable up to 7.0 ns which destabilizes after it. The secretase-berberine complex (orange) is not stable at the start and becomes stable after 5.5 ns. The interaction of secretase with berberine is more stable than rivastigmine. Radius of gyration indicates the compactness of protein given in Fig 6B. Results indicate that the protein for berberine complex is more compact as compared to rivastigmine complex. The secretase-rivastigmine complex is less compact and destabilized at 3200 to 7400 ps, whereas secretase-berberine complex remains compact.

Conclusions

In this study, berberine was isolated from *Berberis lycium* through bioassays guided method. Methanolic extract of *Berberis lycium* significantly reduced acetylcholinesterase activity. Compound isolated from its active fraction was confirmed as berberine that showed significant




Fig 6. Molecular dynamic simulation analysis for 10 ns. [A] RMSD (nm) and [B] radius of gyration (nm). Here R (blue) shows secretase-rivastigmine complex and B (orange) shows secretase-berberine complex. X-axis indicate time in ns and Y-axis indicate RMSD values in nm.

<https://doi.org/10.1371/journal.pone.0286349.g006>

improvement in aluminium chloride induced Alzheimer's disease model and behavioral studies. The memory patterns of berberine treated AD rats were improved in EPM and MWM tests. Additionally, neurotransmitter levels were enhanced, and β -secretase expression was significantly decreased in brain samples of berberine treated rats. In conclusion, our study reported the presence of berberine in *Berberis lycium* as well as its effectiveness in *in vivo* Alzheimer's disease models. However, future studies on the detailed molecular mechanism of berberine in Alzheimer's disease are recommended.

Supporting information

S1 Fig. Immunoblot for beta-secretase and vinculin. This image was taken at 36 sec of exposure to get clear bands of beta secretase.

(PDF)

S2 Fig. Immunoblot for beta-secretase and vinculin. This image was taken at 26 sec of exposure to get clear bands of vinculin.

(PDF)

S1 Data.
(ZIP)

Author Contributions

Conceptualization: Hammad Ismail.

Data curation: Hammad Ismail, Dania Khalid, Durdana Waseem, Muhammad Umar Ijaz, Ihsan-ul Haq, Muhammad Zeeshan Bhatti.

Formal analysis: Hammad Ismail, Dania Khalid, Durdana Waseem, Muhammad Umar Ijaz, Erum Dilshad, Ihsan-ul Haq, Muhammad Zeeshan Bhatti, Sadaf Anwaar, Madiha Ahmed, Samreen Saleem.

Funding acquisition: Hammad Ismail.

Investigation: Hammad Ismail, Durdana Waseem, Muhammad Umar Ijaz, Ihsan-ul Haq, Muhammad Zeeshan Bhatti.

Methodology: Hammad Ismail, Dania Khalid, Durdana Waseem, Muhammad Umar Ijaz, Ihsan-ul Haq, Muhammad Zeeshan Bhatti.

Project administration: Hammad Ismail.

Resources: Hammad Ismail, Durdana Waseem, Ihsan-ul Haq.

Software: Hammad Ismail, Dania Khalid, Muhammad Zeeshan Bhatti.

Supervision: Hammad Ismail.

Validation: Hammad Ismail, Durdana Waseem.

Visualization: Hammad Ismail, Durdana Waseem.

Writing – original draft: Hammad Ismail, Erum Dilshad, Sadaf Anwaar, Madiha Ahmed, Samreen Saleem.

Writing – review & editing: Hammad Ismail, Durdana Waseem, Muhammad Zeeshan Bhatti.

References

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. *Archives of Neurology*. 2003; 60(8):1119–22. <https://doi.org/10.1001/archneur.60.8.1119> PMID: 12925369
2. Dua T, Seeher KM, Sivananthan S, Chowdhary N, Pot AM, Saxena S. World health organization's global action plan on the public health response to dementia 2017–2025. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. 2017; 13(7):1450–1.
3. Ernst RL, Hay JW. Economic research on Alzheimer disease: a review of the literature. *Alzheimer Disease and Associated Disorders*. 1997; 11:135–45. PMID: 9437458
4. Lengel D, Romm ZL, Bostwick A, Huh JW, Snyder NW, Smith GM, et al. Glucocorticoid receptor over-expression in the dorsal hippocampus attenuates spatial learning and synaptic plasticity deficits after pediatric traumatic brain injury. *Journal of Neurotrauma*. 2022; 39(13–14):979–98. <https://doi.org/10.1089/neu.2022.0012> PMID: 35293260
5. Kawamata J, Shimohama S. Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases. *Journal of Alzheimer's Disease*. 2011; 24(s2):95–109. <https://doi.org/10.3233/JAD-2011-110173> PMID: 21403387
6. Cifariello A, Pompili A, Gasbarri A. 5-HT7 receptors in the modulation of cognitive processes. *Behavioural Brain Research*. 2008; 195(1):171–9. <https://doi.org/10.1016/j.bbr.2007.12.012> PMID: 18243350

7. Khan T, Khan IA, Rehman A. A composite review of *Berberis* in service of humanity-in-trouble: an ethnopharmacological and pharmacognosic perspective. *Journal of Biodiversity and Environmental Sciences*. 2015; 6:21–33.
8. Ismail H, Gillespie AL, Calderwood D, Iqbal H, Gallagher C, Chevallier OP, et al. The health promoting bioactivities of *Lactuca sativa* can be enhanced by genetic modulation of plant secondary metabolites. *Metabolites*. 2019; 9(5):97.
9. Ali H, Uddin S, Jalal S. Chemistry and biological activities of *Berberis lycium* Royle. *Journal of Biologically Active Products from Nature*. 2015; 5(5):295–312.
10. Sajid M, Khan MR, Ismail H, Latif S, Rahim AA, Mehboob R, et al. Antidiabetic and antioxidant potential of *Alnus nitida* leaves in alloxan induced diabetic rats. *Journal of Ethnopharmacology*. 2020; 251:112544.
11. Khan I, Najeebullah S, Ali M, Shinwari ZK. Phytopharmacological and ethnomedicinal uses of the Genus *Berberis* (Berberidaceae): A review. *Tropical Journal of Pharmaceutical Research*. 2016; 15(9):2047–57.
12. Khan T, Khan IA, Rehman A. Investigations in to ecological consequences and threats from ethnoecological and ethnobotanical practices across Karakorum mountain ranges: A case study *Berberis*. *Current World Environment*. 2014; 9(3):713.
13. George M, Joseph L, James S. Phytochemical and pharmacological screening of anti-inflammatory activity of *Berberis lycium* root extract. *Pharmacophore*. 2016; 7(1):1–5.
14. Belwal T, Bisht A, Devkota HP, Ullah H, Khan H, Pandey A, et al. Phytopharmacology and clinical updates of *Berberis* species against diabetes and other metabolic diseases. *Frontiers in Pharmacology*. 2020; 11:1–27.
15. Parra SA, Gaur K, Ranawat LS, Rather MI. An overview on various aspects of plant *Berberis Lycium* Royale. *American Journal of Pharmacological Sciences*. 2018; 6(1):19–24.
16. Ismail H, Rasheed A, Haq I-u, Jafri L, Ullah N, Dilshad E, et al. Five indigenous plants of Pakistan with antinociceptive, anti-inflammatory, antidepressant, and anticoagulant properties in Sprague Dawley rats. *Evidence-based Complementary and Alternative Medicine*. 2017; 2017:1–10. <https://doi.org/10.1155/2017/7849501> PMID: 29348774
17. Justin Thenmozhi A, William Raja TR, Manivasagam T, Janakiraman U, Essa MM. Hesperidin ameliorates cognitive dysfunction, oxidative stress and apoptosis against aluminium chloride induced rat model of Alzheimer's disease. *Nutritional Neuroscience*. 2017; 20(6):360–8. <https://doi.org/10.1080/1028415X.2016.1144846> PMID: 26878879
18. Hashmi WJ, Ismail H, Mehmood F, Mirza B. Neuroprotective, antidiabetic and antioxidant effect of *Hedera nepalensis* and lupeol against STZ+ AICl 3 induced rats model. *DARU Journal of Pharmaceutical Sciences*. 2018; 26(2):179–90.
19. Mushtaq A, Ali S, Tahir MN, Ismail H, Mirza B, Saadiq M, et al. New bioactive heteroleptic copper (II) carboxylates: structure, enzymatic and DNA-binding studies. *Acta Chimica Slovenica*. 2017; 64(2):397–408. <https://doi.org/10.17344/acsi.2017.3250> PMID: 28621397
20. Majid M, Khan MR, Shah NA, Haq IU, Farooq MA, Ullah S, et al. Studies on phytochemical, antioxidant, anti-inflammatory and analgesic activities of *Euphorbia dracunculoides*. *BMC Complementary and Alternative Medicine*. 2015; 15(1):1–15.
21. Akowuah G, Okechukwu P, Chiam N. Evaluation of HPLC and spectrophotometric methods for analysis of bioactive constituent berberine in stem extracts of *Coscinium fenestratum*. *Acta Chromatographica*. 2014; 26(2):243–54.
22. Sherazi S, Kandhro A, Mahesar S, Bhanger M, Talpur MY, Arain S. Application of transmission FT-IR spectroscopy for the trans fat determination in the industrially processed edible oils. *Food Chemistry*. 2009; 114(1):323–7.
23. Guideline. OECD guideline for the testing of chemicals. The Hershberger. 2001; 601:858.
24. Naseem S, Ismail H. In vitro and in vivo evaluations of antioxidative, anti-Alzheimer, antidiabetic and anticancer potentials of hydroponically and soil grown *Lactuca sativa*. *BMC Complementary Medicine and Therapies*. 2022; 22(1):1–18.
25. Bhalla P, Garg M, Dhawan D. Protective role of lithium during aluminium-induced neurotoxicity. *Neurochemistry International*. 2010; 56(2):256–62. <https://doi.org/10.1016/j.neuint.2009.10.009> PMID: 19895864
26. Hashmi WJ, Ismail H, Jafri L, Mirza B. Ethnopharmacological activity of *Hedera nepalensis* K. Koch extracts and lupeol against alloxan-induced type I diabetes. *Brazilian Journal of Pharmaceutical Sciences*. 2020; 56:1–15.
27. Aebi H. Catalase in vitro. *Methods in Enzymology*. 105: Elsevier; 1984. p. 121–6.

28. Ellman GL. Tissue sulfhydryl groups. *Archives of Biochemistry and Biophysics*. 1959; 82(1):70–7. [https://doi.org/10.1016/0003-9861\(59\)90090-6](https://doi.org/10.1016/0003-9861(59)90090-6) PMID: 13650640
29. Bannister JV, Calabrese L. Assays for superoxide dismutase. *Methods of Biochemical Analysis*. 1987; 32:279–312. <https://doi.org/10.1002/9780470110539.ch5> PMID: 3033431
30. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Analytical Biochemistry*. 1979; 95(2):351–8. [https://doi.org/10.1016/0003-2697\(79\)90738-3](https://doi.org/10.1016/0003-2697(79)90738-3) PMID: 36810
31. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical Biochemistry*. 1976; 72(1–2):248–54. <https://doi.org/10.1006/abio.1976.9999> PMID: 942051
32. Waseem D, Khan GM, Haq I-u, Rashid U, Syed DN. The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbonyl) benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling. *Toxicology and Applied Pharmacology*. 2020; 401:115091. <https://doi.org/10.1016/j.taap.2020.115091> PMID: 32525019
33. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of Computational Chemistry*. 2010; 31(2):455–61. <https://doi.org/10.1002/jcc.21334> PMID: 19499576
34. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Scientific Reports*. 2017; 7(1):1–13.
35. Lemkul JA. From proteins to perturbed hamiltonians: A suite of tutorials for the GROMACS-2018 molecular simulation package [article v1. 0]. *Living Journal of Computational Molecular Science*. 2019; 1(5068.10):1–53.
36. Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, Shim J, et al. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. *Journal of Computational Chemistry*. 2010; 31(4):671–90. <https://doi.org/10.1002/jcc.21367> PMID: 19575467
37. Mukherjee PK, Kumar V, Mal M, Houghton PJ. Acetylcholinesterase inhibitors from plants. *Phytomedicine*. 2007; 14(4):289–300. <https://doi.org/10.1016/j.phymed.2007.02.002> PMID: 17346955
38. Hampel H, Mesulam M-M, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. *Brain*. 2018; 141(7):1917–33. <https://doi.org/10.1093/brain/awy132> PMID: 29850777
39. Malakooti N, Fowler C, Volitakis I, McLean C, Kim R, Bush A, et al. The Down syndrome-associated protein, regulator of calcineurin-1, is altered in Alzheimer's disease and dementia with Lewy bodies. *Journal of Alzheimer's disease & Parkinsonism*. 2019; 9(2):1–17.
40. Lima JA, Hamerski L. Alkaloids as potential multi-target drugs to treat Alzheimer's disease. *Studies in Natural Products Chemistry*. 2019; 61:301–34.
41. Kong Y, Li L, Zhao L-G, Yu P, Li D-D. A patent review of berberine and its derivatives with various pharmacological activities (2016–2020). *Expert Opinion on Therapeutic Patents*. 2022; 32(2):211–23. <https://doi.org/10.1080/13543776.2021.1974001> PMID: 34455891
42. Lee B, Sur B, Shim I, Lee H, Hahn D-H. Phellodendron amurense and its major alkaloid compound, berberine ameliorates scopolamine-induced neuronal impairment and memory dysfunction in rats. *The Korean Journal of Physiology & Pharmacology*. 2012; 16(2):79–89. <https://doi.org/10.4196/kjpp.2012.16.2.79> PMID: 22563252
43. Cho K-M, Yoo I-D, Kim W-G. 8-hydroxydihydrochelerythrine and 8-hydroxydihydrosanguinarine with a potent acetylcholinesterase inhibitory activity from *Chelidonium majus* L. *Biological and Pharmaceutical Bulletin*. 2006; 29(11):2317–20.
44. Battu SK, Repka MA, Maddineni S, Chittiboyina AG, Avery MA, Majumdar S. Physicochemical characterization of berberine chloride: a perspective in the development of a solution dosage form for oral delivery. *AAPS PharmSciTech*. 2010; 11(3):1466–75. <https://doi.org/10.1208/s12249-010-9520-y> PMID: 20842541
45. Naika HR, Krishna V. Micropropagation, isolation and characterization of berberine from the leaves of *Naravelia zeylanica* (L.) DC. *Research Journal of Medicinal Plants*. 2008; 2:1–9.
46. Hasada K, Yoshida T, Yamazaki T, Sugimoto N, Nishimura T, Nagatsu A, et al. Application of 1 H-NMR spectroscopy to validation of berberine alkaloid reagents and to chemical evaluation of Coptidis Rhizoma. *Journal of Natural Medicines*. 2011; 65:262–7. <https://doi.org/10.1007/s11418-010-0490-x> PMID: 21188644
47. Patil JB, Kim J, Jayaprakasha G. Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway. *European Journal of Pharmacology*. 2010; 645(1–3):70–8. <https://doi.org/10.1016/j.ejphar.2010.07.037> PMID: 20691179

48. Mehla J, Lacoursiere SG, Lapointe V, McNaughton BL, Sutherland RJ, McDonald RJ, et al. Age-dependent behavioral and biochemical characterization of single APP knock-in mouse (APPNL-GF/NL-GF) model of Alzheimer's disease. *Neurobiology of Aging*. 2019; 75:25–37. <https://doi.org/10.1016/j.neurobiolaging.2018.10.026> PMID: 30508733
49. Aski ML, Rezvani ME, Khaksari M, Hafizi Z, Pirmoradi Z, Niknazar S, et al. Neuroprotective effect of berberine chloride on cognitive impairment and hippocampal damage in experimental model of vascular dementia. *Iranian Journal of Basic Medical Sciences*. 2018; 21(1):53. <https://doi.org/10.22038/IJBMS.2017.23195.5865> PMID: 29372037
50. Jung HA, Min B-S, Yokozawa T, Lee J-H, Kim YS, Choi JS. Anti-Alzheimer and antioxidant activities of *Coptidis Rhizoma* alkaloids. *Biological and Pharmaceutical Bulletin*. 2009; 32(8):1433–8.
51. Hussien HM, Abd-Elmegied A, Ghareeb DA, Hafez HS, Ahmed HE, Abd El-moneam N. Neuroprotective effect of berberine against environmental heavy metals-induced neurotoxicity and Alzheimer's-like disease in rats. *Food and Chemical Toxicology*. 2018; 111:432–44. <https://doi.org/10.1016/j.fct.2017.11.025> PMID: 29170048
52. Murakami K, Murata N, Noda Y, Tahara S, Kaneko T, Kinoshita N, et al. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of Alzheimer disease. *Journal of Biological Chemistry*. 2011; 286(52):44557–68.
53. Nardone R, Höller Y, Thomschewski A, Kunz AB, Lochner P, Golaszewski S, et al. Dopamine differently modulates central cholinergic circuits in patients with Alzheimer disease and CADASIL. *Journal of Neural Transmission*. 2014; 121(10):1313–20. <https://doi.org/10.1007/s00702-014-1195-1> PMID: 24677024
54. Pan X, Kaminga AC, Wen SW, Wu X, Acheampong K, Liu A. Dopamine and dopamine receptors in Alzheimer's disease: a systematic review and network meta-analysis. *Frontiers in aging neuroscience*. 2019; 11:175. <https://doi.org/10.3389/fnagi.2019.00175> PMID: 31354471
55. Geldenhuys WJ, Van der Schyf CJ. Role of serotonin in Alzheimer's disease. *CNS drugs*. 2011; 25(9):765–81.
56. Fisher JR, Wallace CE, Tripoli DL, Sheline YI, Cirrito JR. Redundant Gs-coupled serotonin receptors regulate amyloid- β metabolism in vivo. *Molecular Neurodegeneration*. 2016; 11(1):1–12.
57. Ambrée O, Richter H, Sachser N, Lewejohann L, Dere E, de Souza Silva MA, et al. Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease. *Neurobiology of Aging*. 2009; 30(8):1192–204. <https://doi.org/10.1016/j.neurobiolaging.2007.11.010> PMID: 18079024
58. Holm P, Ettrup A, Klein AB, Santini MA, El-Sayed M, Elvang AB, et al. Plaque deposition dependent decrease in 5-HT 2A serotonin receptor in A β PPswe/PS1dE9 amyloid overexpressing mice. *Journal of Alzheimer's Disease*. 2010; 20(4):1201–13.
59. Kulkarni SK, Dhir A. On the mechanism of antidepressant-like action of berberine chloride. *European Journal of Pharmacology*. 2008; 589(1–3):163–72. <https://doi.org/10.1016/j.ejphar.2008.05.043> PMID: 18585703
60. Fan J, Zhang K, Jin Y, Li B, Gao S, Zhu J, et al. Pharmacological effects of berberine on mood disorders. *Journal of Cellular and Molecular Medicine*. 2019; 23(1):21–8. <https://doi.org/10.1111/jcmm.13930> PMID: 30450823
61. Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer's disease therapy. *The Lancet Neurology*. 2014; 13(3):319–29.
62. Menting KW, Claassen JA. β -secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease. *Frontiers in Aging Neuroscience*. 2014; 6:165.
63. Cai Z, Wang C, He W, Chen Y. Berberine alleviates amyloid-beta pathology in the brain of APP/PS1 transgenic mice via inhibiting β/γ -secretases activity and enhancing α -secretases. *Current Alzheimer Research*. 2018; 15(11):1045–52.
64. Asai M, Iwata N, Yoshikawa A, Aizaki Y, Ishiura S, Saido TC, et al. Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease A β secretion. *Biochemical and Biophysical Research Communications*. 2007; 352(2):498–502.
65. Yu G, Li Y, Tian Q, Liu R, Wang Q, Wang J-Z, et al. Berberine attenuates calyculin A-induced cytotoxicity and Tau hyperphosphorylation in HEK293 cells. *Journal of Alzheimer's Disease*. 2011; 24(3):525–35. <https://doi.org/10.3233/JAD-2011-101779> PMID: 21297267
66. Panahi N, Mahmoudian M, Mortazavi P, Hashjin GS. Effects of berberine on β -secretase activity in a rabbit model of Alzheimer's disease. *Archives of Medical Science: AMS*. 2013; 9(1):146.
67. Durairajan SSK, Liu L-F, Lu J-H, Chen L-L, Yuan Q, Chung SK, et al. Berberine ameliorates β -amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model. *Neurobiology of Aging*. 2012; 33(12):2903–19.

68. Ji H-F, Shen L. Molecular basis of inhibitory activities of berberine against pathogenic enzymes in Alzheimer's disease. *The Scientific World Journal*. 2012; 2012:1–5. <https://doi.org/10.1100/2012/823201> PMID: [22262957](https://pubmed.ncbi.nlm.nih.gov/22262957/)
69. Qadir SA, Kwon MC, Han JG, Ha JH, Chung HS, Ahn J, et al. Effect of different extraction protocols on anticancer and antioxidant activities of *Berberis koreana* bark extracts. *Journal of Bioscience and Bioengineering*. 2009; 107(3):331–8. <https://doi.org/10.1016/j.jbiosc.2008.11.021> PMID: [19269602](https://pubmed.ncbi.nlm.nih.gov/19269602/)